

News Release



February 27, 2025
JCR Pharmaceuticals Co., Ltd.

Translation

Change in Duties of Corporate Officers, Organizational and Personnel Changes

Hyogo, Japan – February 27, 2025 – [JCR Pharmaceuticals Co., Ltd.](#) (TSE 4552; “JCR”) announced today that its Board of Directors resolved at a meeting held today to change in duties of corporate officers, organizational and personnel changes as follows.

1. Change in Duties of Corporate Officers (As of April 1, 2025)

Name	New Area of Supervision	Current Area of Supervision
Makoto Ashida	Senior Director of Production Division and Director of Production Management Unit	Senior Director of Production Division

2. Organizational Changes (As of April 1, 2025)

1. Reorganization of Sales Division

“Kinki Sales Department” will be newly established to facilitate prompt decision-making in the formulation of area strategies and the strengthening of activities. In addition, the areas in charge of “Tokai Keiji Hokuriku Sales Department” and “West Japan Sales Department” will be reorganized, and “Tokai Keiji Hokuriku Sales Department” will be renamed “Central Japan Sales Department.”

2. Establishment of Distribution Measures Department

A part of the groups within the Sales Promotion Department will be promoted, and a new “Distribution Measures Department” will be established.

3. Personnel Changes (As of April 1, 2025)

Name	New Title	Current Title
Shuichi Yasumoto	Director, Central Japan Sales Development, Sales Division	Director, West Japan Sales Development, Sales Division
Hiroyuki Ozaki	Director, Kinki Sales Development, Sales Division	Director, Tokai Keiji Hokuriku Sales Development, Sales Division
Hironori Tokura	Director, West Japan Sales Development, Sales Division	Manager, North Kanto Koshinetsu area, East Japan Sales Development, Sales Division
Masamitsu Kubo	Director, Distribution Measures Development, Sales Division	Deputy Director, Sales Promotion Development, Sales Division

About JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 49-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients' lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), MPS II, MPS IIIA and B (Sanfilippo syndrome type A and B), and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and belief – benefit all our stakeholders, including patients, partners, and employees. For more information, please visit <https://www.jcrpharm.co.jp/en/site/en/>.

Contact:

Investors & Media:

JCR Pharmaceuticals Co., Ltd.

Corporate Communications

ir-info@jp.jcrpharm.com

###